Xvivo Perfusion Q4: Strong profitability

Research Note

2018-02-09

10:30

Sales in Q4 came in slightly higher than our forecast. The outcome, combined with lower-than-expected operating costs, resulted in an EBITDA that exceeded our expectations. With obtained CPT codes and progression according to plan in the research portfolio, Xvivo Perfusion is poised for a strong 2018. Our fair value remains unchanged at SEK 105 per share.

AN

Arvid Necander

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.